MA34286B1 - Compositions pharmaceutiques et procédés pour les fabriquer - Google Patents
Compositions pharmaceutiques et procédés pour les fabriquerInfo
- Publication number
- MA34286B1 MA34286B1 MA35417A MA35417A MA34286B1 MA 34286 B1 MA34286 B1 MA 34286B1 MA 35417 A MA35417 A MA 35417A MA 35417 A MA35417 A MA 35417A MA 34286 B1 MA34286 B1 MA 34286B1
- Authority
- MA
- Morocco
- Prior art keywords
- making
- methods
- pharmaceutical compositions
- relates
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des compositions pharmaceutiques comprenant environ 10 mg de pazopanib par mL de composition et d'environ 2 à environ 13 % p/p de cyclodextrine modifiée. L'invention concerne également des procédés de fabrication de ces compositions.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33171510P | 2010-05-05 | 2010-05-05 | |
PCT/US2011/035363 WO2011140343A1 (fr) | 2010-05-05 | 2011-05-05 | Compositions pharmaceutiques et procédés pour les fabriquer |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34286B1 true MA34286B1 (fr) | 2013-06-01 |
Family
ID=44851507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA35417A MA34286B1 (fr) | 2010-05-05 | 2011-05-05 | Compositions pharmaceutiques et procédés pour les fabriquer |
Country Status (26)
Country | Link |
---|---|
US (3) | US20120028918A1 (fr) |
EP (1) | EP2566331B1 (fr) |
JP (1) | JP5835717B2 (fr) |
KR (1) | KR20130071434A (fr) |
CN (1) | CN102970871A (fr) |
AR (1) | AR081364A1 (fr) |
AU (1) | AU2011247995B2 (fr) |
BR (1) | BR112012028291A2 (fr) |
CA (1) | CA2798386A1 (fr) |
CL (1) | CL2012003075A1 (fr) |
CO (1) | CO6640262A2 (fr) |
CR (1) | CR20120556A (fr) |
DO (1) | DOP2012000281A (fr) |
EA (1) | EA201291168A1 (fr) |
ES (1) | ES2519615T3 (fr) |
HK (1) | HK1175947A1 (fr) |
IL (1) | IL222751A0 (fr) |
MA (1) | MA34286B1 (fr) |
MX (1) | MX2012012837A (fr) |
NZ (1) | NZ603411A (fr) |
PE (1) | PE20130217A1 (fr) |
SG (1) | SG185087A1 (fr) |
TW (1) | TW201206908A (fr) |
UY (1) | UY33367A (fr) |
WO (1) | WO2011140343A1 (fr) |
ZA (1) | ZA201208265B (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
ES2493641T3 (es) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
UY33367A (es) * | 2010-05-05 | 2011-10-31 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmacéuticas y métodos para su elaboración |
JP6063382B2 (ja) | 2010-08-05 | 2017-01-18 | フォーサイト・ビジョン フォー・インコーポレーテッド | 治療薬を眼の埋め込み体へと注入するためのシステム |
WO2012068549A2 (fr) | 2010-11-19 | 2012-05-24 | Forsight Vision4, Inc. | Formulations d'agents thérapeutiques pour des dispositifs implantés |
CA2848385C (fr) | 2011-09-16 | 2021-10-26 | Forsight Vision4, Inc. | Methodes et appareil d'echange d'un fluide d'un dispositif implantable |
US20150335609A1 (en) * | 2012-02-17 | 2015-11-26 | Pharmacyclics, Inc. | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof |
EP3509387B1 (fr) * | 2012-03-08 | 2021-07-28 | Samsung Electronics Co., Ltd. | Procédé de commande de services dans un système de communication sans fil |
EP2968113B8 (fr) * | 2013-03-14 | 2020-10-28 | Forsight Vision4, Inc. | Systèmes pour l'administration intra-oculaire entretenue de composés à faible solubilité provenant d'un implant de système de pose d'orifice |
ES2813877T3 (es) | 2013-08-28 | 2021-03-25 | Crown Bioscience Inc Taicang | Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos |
MY182793A (en) * | 2014-08-08 | 2021-02-05 | Forsight Vision4 Inc | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
CA2967330A1 (fr) | 2014-11-10 | 2016-05-19 | Forsight Vision4, Inc. | Dispositifs expansibles d'administration de medicament et methode d'utilisation |
US11129900B2 (en) | 2014-12-25 | 2021-09-28 | Kyoto University | Cytophilic peptide-fused high-density lipoprotein, and delivery of drug to posterior segment of eye by ocular installation of said fusion |
JP7009384B2 (ja) | 2016-04-05 | 2022-01-25 | フォーサイト・ビジョン フォー・インコーポレーテッド | 移植可能な眼薬送達デバイス |
CN110769853B (zh) * | 2017-04-17 | 2022-06-03 | 北京生命科学研究所 | 治疗雄性衰老 |
US11174253B2 (en) | 2017-08-02 | 2021-11-16 | Alphala Co., Ltd. | Compound and pharmaceutical composition containing the same |
ES2956225T3 (es) * | 2018-06-07 | 2023-12-15 | Pfizer | Formulación acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea |
CN113350351A (zh) * | 2020-03-13 | 2021-09-07 | 青晓制药公司 | 帕唑帕尼的应用、药物组合物、注射液及制备方法和应用 |
US20240050429A1 (en) * | 2022-08-10 | 2024-02-15 | Qx Therapeutics, Inc. | Pazopanib pharmaceutical composition, injection and preparation method and use thereof |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8904296D0 (sv) * | 1989-12-21 | 1989-12-21 | Pharmacia Ab | Transdermal system |
US7893040B2 (en) * | 2005-07-22 | 2011-02-22 | Oculis Ehf | Cyclodextrin nanotechnology for ophthalmic drug delivery |
CN101370505B (zh) * | 2005-11-29 | 2012-03-21 | 史密丝克莱恩比彻姆公司 | 新生血管性眼病如黄斑变性、血管样纹、葡萄膜炎和黄斑水肿的治疗 |
AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
JP2009534409A (ja) * | 2006-04-18 | 2009-09-24 | イーケーアール セラピューティクス, インク. | 予備混合即時使用静脈内ボーラス組成物および使用方法 |
ES2830024T3 (es) * | 2007-10-19 | 2021-06-02 | Novartis Ag | Composiciones y métodos para el tratamiento del edema macular |
WO2009097446A1 (fr) * | 2008-01-30 | 2009-08-06 | Genentech, Inc. | Composés de pyrazolopyrimidine inhibant pi3k et procédés d'utilisation |
AU2010273254A1 (en) * | 2009-07-16 | 2012-02-02 | Glaxo Wellcome Manufacturing Pte Ltd | Treatment method |
US20120232102A1 (en) * | 2009-09-30 | 2012-09-13 | Chun-Fang Xu | Methods Of Administration And Treatment |
UY33164A (es) * | 2010-01-06 | 2011-08-31 | Glaxo Wellcome Mfg Pte Ltd | Metodo de tratamiento |
US20130023550A1 (en) * | 2010-05-05 | 2013-01-24 | Glaxo Wellcome Manufacturing Pte, Ltd | Pharmaceutical compositions and methods of making same |
UY33367A (es) * | 2010-05-05 | 2011-10-31 | Glaxo Wellcome Mfg Pte Ltd | Composiciones farmacéuticas y métodos para su elaboración |
-
2011
- 2011-05-03 UY UY0001033367A patent/UY33367A/es unknown
- 2011-05-03 AR ARP110101514A patent/AR081364A1/es unknown
- 2011-05-03 TW TW100115488A patent/TW201206908A/zh unknown
- 2011-05-05 NZ NZ603411A patent/NZ603411A/en not_active IP Right Cessation
- 2011-05-05 ES ES11778348.0T patent/ES2519615T3/es active Active
- 2011-05-05 US US13/133,030 patent/US20120028918A1/en not_active Abandoned
- 2011-05-05 CA CA2798386A patent/CA2798386A1/fr not_active Abandoned
- 2011-05-05 PE PE2012002115A patent/PE20130217A1/es not_active Application Discontinuation
- 2011-05-05 JP JP2013509268A patent/JP5835717B2/ja not_active Expired - Fee Related
- 2011-05-05 CN CN2011800333447A patent/CN102970871A/zh active Pending
- 2011-05-05 WO PCT/US2011/035363 patent/WO2011140343A1/fr active Application Filing
- 2011-05-05 BR BR112012028291A patent/BR112012028291A2/pt not_active IP Right Cessation
- 2011-05-05 KR KR1020127031739A patent/KR20130071434A/ko not_active Application Discontinuation
- 2011-05-05 MX MX2012012837A patent/MX2012012837A/es active IP Right Grant
- 2011-05-05 SG SG2012079968A patent/SG185087A1/en unknown
- 2011-05-05 US US13/101,689 patent/US20110281901A1/en not_active Abandoned
- 2011-05-05 MA MA35417A patent/MA34286B1/fr unknown
- 2011-05-05 EP EP11778348.0A patent/EP2566331B1/fr active Active
- 2011-05-05 EA EA201291168A patent/EA201291168A1/ru unknown
- 2011-05-05 AU AU2011247995A patent/AU2011247995B2/en not_active Ceased
-
2012
- 2012-10-29 IL IL222751A patent/IL222751A0/en unknown
- 2012-10-31 CL CL2012003075A patent/CL2012003075A1/es unknown
- 2012-11-01 CR CR20120556A patent/CR20120556A/es unknown
- 2012-11-02 DO DO2012000281A patent/DOP2012000281A/es unknown
- 2012-11-02 ZA ZA2012/08265A patent/ZA201208265B/en unknown
- 2012-12-05 CO CO12221016A patent/CO6640262A2/es not_active Application Discontinuation
-
2013
- 2013-03-14 HK HK13103191.6A patent/HK1175947A1/xx not_active IP Right Cessation
-
2015
- 2015-05-06 US US14/705,298 patent/US20150231265A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2011247995B2 (en) | 2014-07-31 |
ES2519615T3 (es) | 2014-11-07 |
IL222751A0 (en) | 2012-12-31 |
SG185087A1 (en) | 2012-12-28 |
WO2011140343A1 (fr) | 2011-11-10 |
US20120028918A1 (en) | 2012-02-02 |
AU2011247995A1 (en) | 2012-12-13 |
CR20120556A (es) | 2013-02-20 |
KR20130071434A (ko) | 2013-06-28 |
EA201291168A1 (ru) | 2013-06-28 |
ZA201208265B (en) | 2013-07-31 |
UY33367A (es) | 2011-10-31 |
HK1175947A1 (en) | 2013-07-19 |
JP5835717B2 (ja) | 2015-12-24 |
BR112012028291A2 (pt) | 2015-09-15 |
CN102970871A (zh) | 2013-03-13 |
CA2798386A1 (fr) | 2011-11-10 |
CL2012003075A1 (es) | 2013-03-08 |
PE20130217A1 (es) | 2013-03-21 |
MX2012012837A (es) | 2013-01-24 |
US20150231265A1 (en) | 2015-08-20 |
TW201206908A (en) | 2012-02-16 |
DOP2012000281A (es) | 2013-05-31 |
JP2013525501A (ja) | 2013-06-20 |
NZ603411A (en) | 2014-10-31 |
US20110281901A1 (en) | 2011-11-17 |
AR081364A1 (es) | 2012-08-29 |
CO6640262A2 (es) | 2013-03-22 |
EP2566331A1 (fr) | 2013-03-13 |
EP2566331A4 (fr) | 2013-09-18 |
EP2566331B1 (fr) | 2014-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34286B1 (fr) | Compositions pharmaceutiques et procédés pour les fabriquer | |
MA33197B1 (fr) | Inhibiteurs de tripeptide époxy cétone protéases cristallines | |
SG10201405377XA (en) | Compositions and methods for antibodies targeting complement protein c5 | |
EA200900613A1 (ru) | Спирокетоновые ингибиторы ацетил-коа-карбоксилаз | |
TW200621313A (en) | Pharmaceutical compositions | |
EP2086540B8 (fr) | Composés de triazolopyridine pour le traitement de maladies dégénératives et inflammatoires | |
MY166045A (en) | Abeta antibody formulation | |
HUS1800013I1 (hu) | Cladribine tartalmú orális gyógyászati készítmény | |
MA33208B1 (fr) | Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci | |
UA94264C2 (ru) | Стабильная жидкая фармацевтическая композиция, которая содержит антагонистическое моноклональное антитело к cd40 | |
MA31502B1 (fr) | Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation | |
TW200621317A (en) | Pharmaceutical composition | |
MX2012003555A (es) | Composicion farmaceutica que comprende acido graso omega-3 y derivado hidroxi de una estatina y metodos para usar la misma. | |
MA31898B1 (fr) | Compositions pharmaceutiques | |
EA201070827A1 (ru) | Способы и композиции для перорального введения белковых и пептидных терапевтических средств | |
MX2012007375A (es) | 3-ceto-n-propargil 1-aminoindano. | |
UA103930C2 (ru) | Соединения и композиция для лечения паразитарных болезней | |
UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
MA32776B1 (fr) | Inhibiteurs de l'akt et de la p70 s6 kinase | |
WO2007066337A3 (fr) | Derives chimiques ameliores de jasmonate, compositions pharmaceutiques et procedes d'utilisation correspondants | |
MA33679B1 (fr) | Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole | |
WO2010049449A3 (fr) | Nouveaux sels de sunitinib | |
MA31706B1 (fr) | Formulations galéniques de composés organiques | |
UA95088C2 (ru) | Композиция, которая содержит наночастички связанные с биосовместимым полимером противоракового агента и снижает аллопецию при химиотерапии, способ ее получения | |
MX2010001243A (es) | Composicion anti-inflamatoria. |